{"id":"NCT00734071","sponsor":"Takeda","briefTitle":"An Efficacy and Safety Study of Vortioxetine (Lu AA21004) in Treating Generalized Anxiety Disorder","officialTitle":"A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Fixed-Dose Study Comparing the Efficacy and Safety of Single Dose of Lu AA21004 in Acute Treatment of Adults With Generalized Anxiety Disorder","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2008-06","primaryCompletion":"2009-01","completion":"2009-03","firstPosted":"2008-08-13","resultsPosted":"2013-12-18","lastUpdate":"2013-12-18"},"enrollment":304,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Generalized Anxiety Disorder"],"interventions":[{"type":"DRUG","name":"Vortioxetine","otherNames":["Lu AA21004","BrintellixÂ®"]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Placebo","type":"PLACEBO_COMPARATOR"},{"label":"Vortioxetine 5 mg","type":"EXPERIMENTAL"}],"summary":"The purpose of this study is to determine the safety and efficacy of vortioxetine, once daily (QD), in treating Generalized Anxiety Disorder.","primaryOutcome":{"measure":"Change From Baseline in the Hamilton Anxiety Scale (HAM-A) Total Score at Week 8","timeFrame":"Baseline to Week 8","effectByArm":[{"arm":"Placebo","deltaMin":-13.16,"sd":0.655},{"arm":"Vortioxetine 5 mg","deltaMin":-12.57,"sd":0.646}],"pValues":[{"comp":"OG000 vs OG001","p":"0.518"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":12},"locations":{"siteCount":33,"countries":["United States"]},"refs":{"pmids":["22901736"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":3,"n":151},"commonTop":["Nausea","Headache","Dry mouth","Dizziness","Diarrhoea"]}}